These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29681484)

  • 1. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
    Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
    Hebner CM; Han B; Brendza KM; Nash M; Sulfab M; Tian Y; Hung M; Fung W; Vivian RW; Trenkle J; Taylor J; Bjornson K; Bondy S; Liu X; Link J; Neyts J; Sakowicz R; Zhong W; Tang H; Schmitz U
    PLoS One; 2012; 7(6):e39163. PubMed ID: 22720059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.
    Xie Y; Ogah CA; Jiang X; Li J; Shen J
    Curr Drug Targets; 2016; 17(13):1560-76. PubMed ID: 26648061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
    Wong KA; Xu S; Martin R; Miller MD; Mo H
    Virology; 2012 Jul; 429(1):57-62. PubMed ID: 22543048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors.
    Enguehard-Gueiffier C; Musiu S; Henry N; Véron JB; Mavel S; Neyts J; Leyssen P; Paeshuyse J; Gueiffier A
    Eur J Med Chem; 2013 Jun; 64():448-63. PubMed ID: 23665801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
    Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
    Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency.
    Cheng Y; Shen J; Peng RZ; Wang GF; Zuo JP; Long YQ
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2900-2906. PubMed ID: 27133482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
    Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: from anti-pestivirus to anti-hepatitis C virus activity.
    Puerstinger G; Paeshuyse J; De Clercq E; Neyts J
    Bioorg Med Chem Lett; 2007 Jan; 17(2):390-3. PubMed ID: 17084081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.
    Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.
    Hirashima S; Suzuki T; Ishida T; Noji S; Yata S; Ando I; Komatsu M; Ikeda S; Hashimoto H
    J Med Chem; 2006 Jul; 49(15):4721-36. PubMed ID: 16854079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; Omar FA
    Eur J Med Chem; 2019 Dec; 184():111747. PubMed ID: 31604164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism.
    Leivers M; Miller JF; Chan SA; Lauchli R; Liehr S; Mo W; Ton T; Turner EM; Youngman M; Falls JG; Long S; Mathis A; Walker J
    J Med Chem; 2014 Mar; 57(5):1964-75. PubMed ID: 24224729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.